Y. Tung

Is it feasible to discuss an advance directive with a Chinese patient with advanced malignancy? A prospective cohort study.

S. Lo, W. Sze, S. Wong, 2012, Hong Kong medical journal = Xianggang yi xue za zhi.

The implementation of an end-of-life integrated care pathway in a Chinese population.

S. Lo, W. Sze, Chun-hung Chan, 2009, International journal of palliative nursing.

MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer

H. Hsu, Hong-Yu Tseng, Yen-An Chen, 2019, Molecular Cancer.

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

N. Petrelli, W. Greco, J. Cowens, 1993, Cancer research.

Survey on symptomatic cutaneous manifestations of Epidermal Growth Factor Receptor Inhibitors (EGFRI) in oncology patients at a regional hospital EGFRI

Kk Choi, S. Lo, Y. Chan, 2012 .

Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer

G. Manikhas, J. Pierga, C. Thomssen, 2010 .

MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer

H. Hsu, Yen-An Chen, Li-Mei Chen, 2019, Molecular Cancer.